Valvular & structural heart diseaseRandomised controlled trial
Transcatheter vs. surgical aortic valve replacement in women: the RHEIA trial
- Randomised controlled trial
- non-inferiority
- 48 European centres
Authors' conclusion
Among women with severe aortic stenosis, the incidence of the composite of death, stroke, or rehospitalization at 1 year was lower with TAVI than with surgery.
Study context
- Population
- Women with severe symptomatic AS420 treated as randomized
- Participants
- 443 women
- Comparison
- Transfemoral transcatheter aortic valve implantation (TAVI) vs surgery
- Primary endpoint
- Composite of death, stroke, or (valve, procedure or HF related) rehospitalization
- Follow-up
- 1 year
Primary result
As reported in the abstract
- superiority; two-sided CI
- difference −6.8% (95% CI −13.0% to −.5%); P = 0.034
- non-inferiority met; upper 95% confidence limit −1.5%, margin 6%
- difference −6.8%; P < 0.001
Further findings
Primary endpoint components · 1 year
Death from any cause TAVI .9% · Surgery 2.0%
Stroke
Rehospitalization
Original publication
Transcatheter vs. surgical aortic valve replacement in women: the RHEIA trial. Eur Heart J. Published 2 April 2025. doi:10.1093/eurheartj/ehaf133
Summarised from the published abstract; every number is checked against it